Evaluation of Quality of Life of Patients with Hirsutism Among Turkish Women: A Single-Center Cross-Sectional Study

    Ömer Kutlu
    Image of study
    TLDR Turkish women with hirsutism experience lower quality of life, especially those with PCOS, regardless of hair growth severity.
    In a study of 57 Turkish women with hirsutism, it was found that their quality of life, as measured by the Dermatological Life Quality Index (DLQI), was significantly decreased with a mean score of 9.80 ± 6.50. The study, conducted by Ömer Kutlu, showed no significant correlation between the DLQI and the modified Ferriman-Gallwey (mFG) scores, indicating that the severity of hirsutism did not directly relate to quality of life. However, women with polycystic ovary syndrome (PCOS) had a significantly higher mean DLQI score, suggesting a greater impact on quality of life. Other clinical symptoms like acne, seborrhea, androgenetic alopecia, menstrual irregularity, or acanthosis nigricans were not found to significantly affect quality of life. The location of hair growth, especially on the face, was suggested to have a more substantial impact on quality of life than the total number of affected areas. The study highlighted the need for psychological support for hirsutism patients, particularly those with PCOS. The limitations of the study included its single-center design and the exclusive use of DLQI for quality of life assessment.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results

    Related Community Posts Join

    6 / 24 results

      community AA and Hirsutism but T levels are normal

      in Female  8 upvotes 3 years ago
      27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

      community No, Finasteride as a treatment for MPB was not an "accident"

      in Research/Science  105 upvotes 3 years ago
      Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.

      community Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025

      in Treatment  117 upvotes 2 months ago
      Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

      community Does low HGH leading to hairloss?

      in Research/Science  13 upvotes 9 months ago
      The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

    Related Research

    7 / 7 results